|
Leptospirosis vaccines: Past, present, and future
N Koizumi, H Watanabe
Department of Bacteriology, National Institute of Infectious Diseases 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
Correspondence Address:
H Watanabe
1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640
Japan
It is well known that Leptospira vaccine prevents the disease. However specificity for serovars limits the efficacy of killed whole cell vaccines. Leptospiral antigens that induce cross-protective immunity to the various serovars are sought as new vaccine candidates. In this paper, we have summarized both past and current findings about leptospiral antigens that are conserved among pathogenic leptospires and that induce protective immunity in animal models. The full-length genome sequences of two Leptospira strains have been published and reverse vaccinology has been used to identify leptospiral vaccine candidates. Although humoral immunity is thought to be dominant in protection from leptospiral infection, a role for cell-mediated immunity is now being explored.
How to cite this article:
Koizumi N, Watanabe H. Leptospirosis vaccines: Past, present, and future.J Postgrad Med 2005;51:210-214
|
How to cite this URL:
Koizumi N, Watanabe H. Leptospirosis vaccines: Past, present, and future. J Postgrad Med [serial online] 2005 [cited 2023 Oct 3 ];51:210-214
Available from: https://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=3;spage=210;epage=214;aulast=Koizumi;type=0 |
|
|
|
